Vitality Biopharma Inc (OTCMKTS:VBIO) reported positive preclinical efficacy data for its gut-targeted cannabosides in the cure of colitis. The company has advanced a new class of Hemp drugs, termed as cannabosides, which upon absorption can be targeted and restricted to the gastrointestinal tract, hence avoiding drug psychoactivity and unexpected side effects.
In a preclinical setup of inflammatory bowel disease, cannabosides were able to lower weight loss, reduce damage to the colon, and noticeably improved gastrointestinal health as against the placebo controls.
Vitality’s cannabosides recorded success in treatment of DSS, which is conventionally viewed as extremely challenging, provided that certain FDA-permitted treatments including TNF-alpha inhibitors and corticosteroids have been demonstrated to be ineffective for curing this model. The positive preclinical efficacy report with cannabosides are needed in order for the firm to advance into first-in-man clinical studies.
Independent clinical trial report has indicated that cannabinoids can help bring remission of drug-resistant IBD with just 8 weeks of treatment. Moreover, Vitality recently issued results from a pediatric Crohn’s disease case trial that documents the condition of a kid who achieved remission utilizing cannabis after almost all classes of FDA-permitted IBD drugs were demonstrated to be ineffective.
Vitality’s cannabosides may be particularly useful for pediatric purposes as they are intended to deliver Hemps to the gastrointestinal tract while evading drug psychoactivity, which is explicably preferred by most pediatric gastroenterologists and parents. As per the latest data, around 1.6 million Americans currently suffer from IBD and this figure comprises as many as 80,000 children.
Dr. Brandon Zipp, the Scientific Co-founder of Vitality and Director of R&D, reported that they are thrilled to release this positive report from their cannabosides program, and to continue assessing the utility of their compounds for treatment of Inflammatory Bowel Disease and other major therapeutic applications. This is another instance of company’s team delivering on a key milestone.